CS
CLDX icon

Credit Suisse’s Celldex Therapeutics CLDX Stock Holding History

Credit Suisse’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.15M Buy
51,113
+3,115
+6% +$128K ﹤0.01% 1805
2023
Q4 		$1.9M Buy
47,998
+7,209
+18% +$212K ﹤0.01% 1916
2023
Q3 		$1.12M Sell
40,789
-10,081
-20% -$316K ﹤0.01% 2232
2023
Q2 		$1.73M Buy
50,870
+14,616
+40% +$493K ﹤0.01% 2015
2023
Q1 		$1.3M Buy
36,254
+2,439
+7% +$105K ﹤0.01% 2161
2022
Q4 		$1.51M Sell
33,815
-341
-1% -$12.2K ﹤0.01% 2047
2022
Q3 		$960K Buy
34,156
+4,249
+14% +$130K ﹤0.01% 2364
2022
Q2 		$806K Buy
29,907
+975
+3% +$28.3K ﹤0.01% 2531
2022
Q1 		$986K Buy
28,932
+827
+3% +$26.4K ﹤0.01% 2562
2021
Q4 		$1.09M Sell
28,105
-2,059
-7% -$89.7K ﹤0.01% 3252
2021
Q3 		$1.63M Buy
30,164
+3,742
+14% +$176K ﹤0.01% 2970
2021
Q2 		$883K Sell
26,422
-22,532
-46% -$618K ﹤0.01% 3482
2021
Q1 		$1.01M Sell
48,954
-18,838
-28% -$433K ﹤0.01% 3320
2020
Q4 		$1.19M Buy
+67,792
New +$1.22M ﹤0.01% 3215
2020
Q2 		– Sell
-35,317
Closed -$58K – 3976
2020
Q1 		$58K Buy
+35,317
New +$79.8K ﹤0.01% 3890
2018
Q2 		– Sell
-18,739
Closed -$655K – 3982
2018
Q1 		$655K Buy
18,739
+652
+4% +$25.3K ﹤0.01% 3214
2017
Q4 		$771K Buy
18,087
+2,511
+16% +$108K ﹤0.01% 3174
2017
Q3 		$669K Buy
15,576
+4,107
+36% +$154K ﹤0.01% 3371
2017
Q2 		$425K Sell
11,469
-4,736
-29% -$209K ﹤0.01% 3259
2017
Q1 		$877K Buy
16,205
+9,446
+140% +$492K ﹤0.01% 2963
2016
Q4 		$359K Sell
6,759
-8,736
-56% -$497K ﹤0.01% 3579
2016
Q3 		$938K Sell
15,495
-1,035
-6% -$64.5K ﹤0.01% 3017
2016
Q2 		$1.09M Sell
16,530
-16,257
-50% -$1.03M ﹤0.01% 2845
2016
Q1 		$1.86M Buy
32,787
+17,827
+119% +$2.01M ﹤0.01% 2264
2015
Q4 		$3.52M Buy
14,960
+3,727
+33% +$812K ﹤0.01% 1861
2015
Q3 		$1.78M Sell
11,233
-13,128
-54% -$3.72M ﹤0.01% 2346
2015
Q2 		$9.21M Buy
24,361
+5,279
+28% +$2.1M 0.01% 1299
2015
Q1 		$7.98M Buy
19,082
+458
+2% +$164K 0.01% 1340
2014
Q4 		$5.1M Buy
18,624
+4,701
+34% +$1.17M ﹤0.01% 1739
2014
Q3 		$2.71M Buy
13,923
+3,937
+39% +$858K ﹤0.01% 2243
2014
Q2 		$2.44M Sell
9,986
-6,488
-39% -$1.46M ﹤0.01% 2554
2014
Q1 		$4.37M Buy
16,474
+6,977
+73% +$2.67M ﹤0.01% 1870
2013
Q4 		$3.45M Buy
9,497
+5,522
+139% +$2.13M ﹤0.01% 2160
2013
Q3 		$2.11M Sell
3,975
-1,826
-31% -$626K ﹤0.01% 2344
2013
Q2 		$1.36M Buy
+5,801
New +$1.14M ﹤0.01% 2560

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Credit Suisse's CLDX Position: Q1 2024 in Review

Credit Suisse increased its Celldex Therapeutics (CLDX) stake by 6.5% in Q1 2024, buying an estimated $128K and bringing the position to 51,113 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1805.

Credit Suisse first reported a position in CLDX in Q2 2013 and has held it in 35 quarters since. The position peaked at $9.21M in Q2 2015. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • Credit Suisse held 51,113 shares of Celldex Therapeutics worth $2.15M as of Q1 2024.
  • Credit Suisse bought 3,115 Celldex Therapeutics shares in Q1 2024, an estimated $128K.
  • Celldex Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1805 holding.
  • Credit Suisse first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 35 quarters since.
  • Credit Suisse's Celldex Therapeutics position peaked at $9.21M in Q2 2015.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.